Using macrophage activation to augment immunotherapy of established tumours.

ABSTRACT:

Background

Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy.

Methods

We and others have reported that 5,6-Dimethylxanthenone-4-acetic-acid (DMXAA, Vadimezan) has the ability to change TAM phenotypes, inducing a tumour microenvironment conducive to antitumour immune responses. We therefore combined DMXAA with active immunotherapies, and evaluated anti-tumour efficacy, immune cell phenotypes (flow cytometry), and tumour microenvironment (RT-PCR).

Results

In several different murine models of immunotherapy for lung cancer, DMX

SUBMITTER: Fridlender ZG 

PROVIDER: S-EPMC3619255 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature